ArticleFrontiers in pharmacology2023

Doxorubicin resistance in breast cancer is mediated via the activation of FABP5/PPARγ and CaMKII signaling pathway.

Nan-Nan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.